Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 12, 2025
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
GlobeNewswire
·
March 12, 2025
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer …
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
GlobeNewswire
·
March 12, 2025
CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial …
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
GlobeNewswire
·
March 12, 2025
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models …
BD² ANNOUNCES FOUR NEW SITES TO JOIN LANDMARK BIPOLAR DISORDER RESEARCH AND CLINICAL CARE NETWORK
GlobeNewswire
·
March 12, 2025
Washington, D.C, March 12, 2025 (GLOBE NEWSWIRE) -- Today, Breakthrough Discoveries for thriving with Bipolar Disorder (BD²) announced four new national institutions to receive $2.3 million each to join the BD² Integrated Network, a collaborative research …
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
GlobeNewswire
·
March 12, 2025
Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults. AD begins with buildup of amyloid beta (Aβ) plaques and neurofibrillary …
OBI Pharma reçoit le prix du « Candidat clinique ADC le plus prometteur à Taïwan »
GlobeNewswire
·
March 12, 2025
TAIPEI, Taïwan, 12 mars 2025 (GLOBE NEWSWIRE) -- Lors du congrès ADC Asia 2025, qui s’est déroulé aujourd’hui (12 mars) à Singapour, la société OBI Pharma (4174.TWO) a reçu le prix du « Candidat clinique ADC le plus prometteur à Taïwan ». Cette distinction …
OBI Pharma erhält Auszeichnung als „vielversprechendster AWK-Kandidat für klinische Studien in Taiwan“
GlobeNewswire
·
March 12, 2025
TAIPEH, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- Auf dem ADC Asia Congress 2025, der heute (12.03.) in Singapur stattgefundenhat, wurde OBI Pharma (4174.TWO) mit dem Preis „Vielversprechendster AWK-Kandidat für klinische Studien in Taiwan“ ausgezeichnet. …
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
GlobeNewswire
·
March 12, 2025
TAIPEI, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award. This recognition follows OBI Pharma’s …
浩鼎 荣获「台湾最具潜力 ADC 临床候选药物奖」
GlobeNewswire
·
March 12, 2025
台湾台北, March 12, 2025 (GLOBE NEWSWIRE) -- 今（3/12）在新加坡举行的「2025亚洲ADC大会」（ADC Asia Congress 2025）晚会宣布，台湾浩鼎生技（4174.TWO）荣获「台湾最具潜力 ADC 临床候选药物奖（Most Promising ADC Clinical Candidate in Taiwan）」；这是自去年底，与国际药厂共同入围「世界ADC大奖」全球前八强之后，浩鼎开发ADC（抗体药物复合体）新药的实力，再度获得国际专业领域肯定。 …
浩鼎 榮獲「台灣最具潛力 ADC 臨床候選藥物獎」
GlobeNewswire
·
March 12, 2025
台灣台北, March 12, 2025 (GLOBE NEWSWIRE) -- 今（3/12）在新加坡舉行的「2025亞洲ADC大會」（ADC Asia Congress 2025 ）晚會宣布，台灣浩鼎生技（4174.TWO）榮獲「台灣最具潛力 ADC 臨床候選藥物獎 （Most Promising ADC Clinical Candidate in Taiwan）」；這是自去年底，與國際藥廠共同入圍「世界ADC大獎」全球前八強之後，浩鼎開發ADC（抗體藥物複合體）新藥的實力，再度獲得國際專業領域肯定。 …
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
GlobeNewswire
·
March 12, 2025
DURHAM, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug …
Theratechnologies présente des données de suppression virologique encourageantes provenant de l’essai PROMISE-US portant sur l’ibalizumab lors de la CROI
GlobeNewswire
·
March 12, 2025
Les résultats montrent des niveaux semblables de charge virale indétectable chez les patients qui reçoivent des traitements comprenant de l’ibalizumab que chez les témoins, malgré un degré de gravité initial du VIH supérieur L’ibalizumab continue de …
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
GlobeNewswire
·
March 12, 2025
MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data highlighting the limitations of using body mass index ( …
La présentation de Therachnologies lors de la CROI met en évidence les limites liées à l’utilisation de l’IMC pour évaluer le risque de maladie cardiovasculaire (CV) chez les personnes vivant avec le VIH
GlobeNewswire
·
March 12, 2025
MONTRÉAL, 12 mars 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, a présenté aujourd’hui des données mettant en évidence les limites …
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
GlobeNewswire
·
March 12, 2025
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination …
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
·
March 12, 2025
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational New Drug (IND) application for FASN Inhibitor TVB- …
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
GlobeNewswire
·
March 12, 2025
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive Silviu Itescu will deliver the Featured Presentation at …
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
·
March 12, 2025
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth …
Prime Biome Reviews And Complaints: A Detailed Study Released That’s Needs to Be Adopted for Which Type of Peoples?
GlobeNewswire
·
March 12, 2025
ST. PETERSBURG, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- This is a comprehensive examination of the groundbreaking research behind Prime Biome. It is a cutting-edge probiotic supplement made to promote gut and skin health, thereby enhancing general well- …
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
GlobeNewswire
·
March 12, 2025
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS …